Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 5, 2013, Pages 407-415

  Deng, Chenhui ^a,b   Liu, Taotao ^c   Zhou, Tianyan ^a,b   Lu, Hua ^c   Cheng, Daohai ^c   Zhong, Xiaobing ^c   Lu, Wei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chinese adult patients; NONMEM; Population pharmacokinetics; Steadystate trough concentrations; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CHINESE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; POPULATION MODEL; RETROSPECTIVE STUDY; STEADY STATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHINA; COMPUTER SIMULATION; CREATININE; DRUG DOSAGE CALCULATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; VANCOMYCIN; YOUNG ADULT;

EID: 84878065627     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201842     Document Type: Article

References (43)

1. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998; 20: 139-148. CrossRef PubMed
2. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98. CrossRef PubMed
3. Kupstaite R, Baranauskaite A, Pileckyte M, Sveikata A, Kadusevicius E, Muckiene G. Severe vancomycin-induced anaphylactic reaction. Medicina (Kaunas). 2010; 46: 30-33. PubMed
4. An S, Hwang E, Kim J, Kim J, Jin H, Jin S, Kyun J, Lee Y, Park H, Choi Y, Lim S, Ye Y. Vancomycin-associated spontaneous cutaneous adverse drug reactions. Allergy, asthma & immunology research. 2011; 3: 194-198. PubMed
5. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008; 62: 168-171. CrossRef PubMed
6. Malacarne P, Bergamasco S, Donadio C. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy. 2006; 52: 178-184. CrossRef PubMed
7. Colares V, Oliveira R, Abdulkader R. Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2006; 21: 3608. PubMed
8. Felix-Getzik E, Sylvia LM. Vancomycin-induced leukocytoclastic vasculitis. Pharmacotherapy. 2009; 29: 846-851. CrossRef PubMed
9. Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother. 2003; 37: 61-65. CrossRef PubMed
10. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49: 507-514. CrossRef PubMed
11. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010; 9: 9-14. CrossRef PubMed
12. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2004; 38: 521-528. PubMed
13. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006; 57: 699-704. CrossRef PubMed
14. Wei H, Liu Y. Analysis of the Clinical Application of Vancomycin Use in Our Hospital. Chin JMAP. 2010; 27: 371-374.
15. Zhang H, WAng W, Liu Y, Ou N. Analysis of therapeutic drug monitoring data of vancomysin. Pharmaceutical and C linical Research. 2009; 17: 257-259.
16. Hu J, Shi Y, Zhang J et al. pharmarcokinetics of vancomycin in elderly and young healthy volunteers. Chin J Infect Chemother. 2003; 3: 5.
17. Zhang H, Wang W, Liu Y. Analysis of therapeutic drug monitoring data of vancomysin. Pharmaceutical and Clinical Research. 2009; 3: 3.
18. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009; 63: 1050-1057. CrossRef PubMed
19. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health. 2006; 2: 6. CrossRef PubMed
20. Al-Kofide H, Zaghloul I, Al-Naim L. Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010; 16: 245-250. CrossRef PubMed
21. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416. CrossRef PubMed
22. Committee J. F. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2008.
23. Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010; 48: 525-533. PubMed
24. Golper T, Noonan H, Elzinga L, Gilbert D, Brummett R, Anderson J, Bennett W. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988; 43: 6 CrossRef PubMed
25. Gery R. WM R, EH C, William F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 32: 5.
26. Ren J, Yang Z. The pharmacokinetics of vancomycin in the hemodialysis patients. Chinese Journal of Hospital Pharmacy. 1994; 10: 440-441.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41. CrossRef PubMed
28. Beal S, Sheiner L. Boeckmann A. NONMEM User's Guide. San Francisco: Division of Pharmacology, University of California; 1999.
29. Lars L, Jakob R, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Meth Prog Bio. 2004; 75: 85-94. CrossRef
30. Jonsson E, Karlsson M. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Meth Prog Bio. 1998; 58: 51-64. CrossRef
31. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl) phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos. 2009; 37: 2061-2068. CrossRef PubMed
32. Ohnishi A, Yano Y, Ishibashi T, Katsube T, Oguma T. Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients. Drug Metab Pharmacokinet. 2005; 20: 415-422. CrossRef PubMed
33. Zhang J, Zhang Y, Shi Y, Rui J, Yu J, Cao G, Wu J. Population pharmacokinetic and pharmacodynamic modeling of norvancomycin. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2008; 27: 275-284. PubMed
34. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25: 433-437. CrossRef PubMed
35. Zhu H, Liu Y, Zeng Q et al. GP diagnosis manual. Shandong, China: Shandong Science and Technology Press; 2003.
36. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984; 36: 803-810. CrossRef PubMed
37. Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010; 48: 525-533. PubMed
38. Dolton M, Xu H, Cheong E, Maitz P, Kennedy P, Gottlieb T, Buono E, McLachlan AJ. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns. 2010; 36: 469-476. CrossRef PubMed
39. Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009; 34: 473-483. CrossRef PubMed
40. Llopis-Salvia P, Jiménez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006; 31: 447-454. CrossRef PubMed
41. Purwonugroho TA, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P. Population pharmacokinetics of vancomycin in Thai patients. Scientific World Journal. 2012; 2012: 762649. CrossRef PubMed
42. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, Riff LJ. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988; 32: 848-852. CrossRef PubMed
43. Wang J-T, Fang C-T, Chen Y-C, Chang S-C. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother. 2001; 47: 246. CrossRef PubMed